Building GSK Oncology R&D
Axel Hoos, M.D., Ph.D., SVP oncology and R&D governance chair, provides an update and the context of GSK’s R&D strategy.
The Story Of Arrowhead Pharmaceuticals’ Adversity Odyssey
Chis Anzalone, Ph.D., CEO of Arrowhead Pharmaceuticals, discusses taking over a biopharmaceutical company shortly before the Great Recession along with other avenues of adversity faced (e.g., FDA hold on a Phase 2 trial) toward bringing this RNAi company to the brink of success.
Why You Need People Like Jana Spes At Your Company
Industry veteran Jana Spes provides some uniquely qualified analysis and guidance on the outsourcing industry and working with CDMOs. Don’t be surprised if you come away thinking for your next outsourcing operations hire, specialization is out, and the Spes model is in.
Jeff Albers’ Blueprint For Blueprint Medicines
Jeff Albers, president and CEO of Blueprint Medicines, discusses his approach to ensuring the biopharma is commercial ready should it garner some pivotal FDA approvals.
A Biopharma That Had To Pivot Twice To Forge Ahead
Not many thriving companies experience disappointing clinical trial results, jump into an entirely new therapeutic area, and emerge with investor support and renewed hope for an entirely different class of patients. Millendo has done it twice.
The Perilous Development Of A Potential Biologic Blockbuster
CytoDyn's leronlimab is under FDA review for Breakthrough Therapy status. Its path from forgotten molecule to near market readiness was riddled with financial and process challenges.
Allogene Therapeutics — The Juggernaut Built On Kite’s Flight
David Chang, M.D., Ph.D., CEO and cofounder of Allogene Therapeutics, shares how the successful exit from Kite Pharma (acquired by Gilead for $11.9 billion in 2017) led to the building of Allogene, a $3.4 billion clinical-stage biopharma developing allogeneic CAR-T therapy.
Why John Sculley Views Healthcare As His “Noble Cause”
John Sculley, the former CEO of Apple who is now an entrepreneur and investor in high-tech startups, discusses where he sees opportunity in the healthcare industry, along with the leaders he views as being just as visionary as Steve Jobs, if not more so.
J&J And Merck Detail How They Are Investing For Impact
Two Big Pharma executives explain how their organizations are investing for impact.
Women On Boards: How We Get From Here To There
Even though females have “arrived” as biotech executives, there’s more to be done: serving as CEOs, advisors, and directors to help companies achieve their missions.
The 5-Step Strategy That Saved Genmab From A Dire Outlook
Jan G. J. van de Winkel, Ph.D., cofounder, president, and CEO since 2010, remembers when Genmab faced some pretty tough decisions.
What 9 Biopharma Trendsetters Expect For 2020 – And Beyond
Although AI, machine learning, and quantum computing will someday improve our ability to forecast the future, for now Life Science Leader continues to seek knowledge from a cross section of life sciences industry execs.
Biotechs Will Make Music In The “Twenty-Twenties”
Outsourced Pharma Chief Editor Louis Garguilo talks with two biotech CEOs about why they believe this industry should expect an infusion of technology and improved productivity in the coming years.
Competing Interests Complicate FDA Reform
With input from two long-time observers of the biopharma industry and its U.S. regulator, this article covers a cross-section of opinions regarding trends and proposals for improving the FDA review process.
BEYOND THE PRINTED PAGE
What Wasn’t Included In The Print Article About Arrowhead’s Adversity Odyssey?
Rob Wright shares enlightening anecdotes from interview of Chris Anzalone, Ph.D., CEO of Arrowhead Pharmaceuticals.
Food For Free – An Example Of How Life Science Cares Approaches Engagement
Food For Free is an example for how Life Science Cares engages with its community of greater Boston.
Gaurav Shah — A Rare Disease Biopharma CEO Shares A Rare Experience
Dr. Gaurav Shah, M.D., CEO of Rocket Pharmaceuticals, shares some of his rare experiences, such as what it is like to be nominated (as a musician) for a GRAMMY award, his company’s upcoming rare disease day, and more.
LIFE SCIENCE LEADER BLOGS
Practical And Psychological Tips For Virtual Conferencing During COVID-19
With many people now forced to work from home as a result of COVID-19, we will undoubtedly see a rise in the use of video conferencing. Here are some practical and psychological tips for connecting virtually and maintaining engagement with employees.
Working From Home While Living In A Coronavirus World
Chief editor Rob Wright shares thoughts and best practices on working from home while living in a coronavirus world.